Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.
Isa R, Horinaka M, Tsukamoto T, Mizuhara K, Fujibayashi Y, Taminishi-Katsuragawa Y, Okamoto H, Yasuda S, Kawaji-Kanayama Y, Matsumura-Kimoto Y, Mizutani S, Shimura Y, Taniwaki M, Sakai T, Kuroda J. Isa R, et al. Int J Mol Sci. 2022 Mar 8;23(6):2919. doi: 10.3390/ijms23062919. Int J Mol Sci. 2022. PMID: 35328342 Free PMC article.
The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era.
Kobayashi T, Kuroda J, Yokota I, Tanba K, Fujino T, Kuwahara S, Isa R, Yamaguchi J, Kawata E, Akaogi T, Uchiyama H, Kaneko H, Uoshima N, Kobayashi Y, Teramukai S, Taniwaki M. Kobayashi T, et al. Among authors: isa r. Blood Cancer J. 2016 Jan 15;6(1):e383. doi: 10.1038/bcj.2015.111. Blood Cancer J. 2016. PMID: 26771809 Free PMC article. No abstract available.
Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia.
Yamaguchi J, Fujino T, Isa R, Nishiyama D, Kuwahara-Ota S, Kawaji Y, Tsukamoto T, Chinen Y, Shimura Y, Kobayashi T, Horiike S, Kohno K, Nakamura S, Kuroda J. Yamaguchi J, et al. Among authors: isa r. Haematologica. 2019 Aug;104(8):e376-e379. doi: 10.3324/haematol.2019.217141. Epub 2019 Apr 11. Haematologica. 2019. PMID: 30975907 Free PMC article. No abstract available.
Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma.
Isa R, Uoshima N, Takahashi R, Nakano-Akamatsu S, Kawata E, Kaneko H, Shimura K, Kamitsuji Y, Takimoto-Shimomura T, Mizutani S, Chinen Y, Ohshiro M, Fujino T, Kawaji Y, Uchiyama H, Sasaki N, Tsukamoto T, Shimura Y, Kobayashi T, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group investigators. Isa R, et al. Ann Hematol. 2020 Jan;99(1):137-145. doi: 10.1007/s00277-019-03859-9. Epub 2019 Nov 25. Ann Hematol. 2020. PMID: 31768675 Clinical Trial.
Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.
Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, Chinen Y, Tanba K, Kuwahara-Ota S, Fujibayashi Y, Nishiyama D, Isa R, Yamaguchi J, Kawaji-Kanayama Y, Kobayashi T, Horiike S, Taniwaki M, Kuroda J. Matsumura-Kimoto Y, et al. Among authors: isa r. Cancer Med. 2020 Jul;9(14):5185-5199. doi: 10.1002/cam4.3136. Epub 2020 May 18. Cancer Med. 2020. PMID: 32420699 Free PMC article.
Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
Kuwahara-Ota S, Shimura Y, Steinebach C, Isa R, Yamaguchi J, Nishiyama D, Fujibayashi Y, Takimoto-Shimomura T, Mizuno Y, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Kobayashi T, Horiike S, Taniwaki M, Gütschow M, Kuroda J. Kuwahara-Ota S, et al. Among authors: isa r. Br J Haematol. 2020 Dec;191(5):784-795. doi: 10.1111/bjh.16881. Epub 2020 Jun 19. Br J Haematol. 2020. PMID: 32558939 Free article.
Toward further simplification of elotuzumab therapy by subcutaneous administration.
Shimura Y, Tsukamoto T, Yamaguchi J, Kuwahara-Ota S, Isa R, Nishiyama D, Kobayashi T, Horiike S, Suzuki A, Kuroda J. Shimura Y, et al. Among authors: isa r. Int J Hematol. 2020 Sep;112(3):427-428. doi: 10.1007/s12185-020-02942-6. Epub 2020 Jul 13. Int J Hematol. 2020. PMID: 32656639 No abstract available.
Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma.
Fujibayashi Y, Isa R, Nishiyama D, Sakamoto-Inada N, Kawasumi N, Yamaguchi J, Kuwahara-Ota S, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Handa H, Kuroda J. Fujibayashi Y, et al. Among authors: isa r. Cancers (Basel). 2020 Aug 6;12(8):2206. doi: 10.3390/cancers12082206. Cancers (Basel). 2020. PMID: 32781708 Free PMC article.
EWSR1 overexpression is a pro-oncogenic event in multiple myeloma.
Nishiyama D, Chinen Y, Isa R, Fujibayashi Y, Kuwahara-Ota S, Yamaguchi J, Takimoto-Shimomura T, Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Handa H, Kuroda J. Nishiyama D, et al. Among authors: isa r. Int J Hematol. 2021 Mar;113(3):381-394. doi: 10.1007/s12185-020-03027-0. Epub 2020 Oct 23. Int J Hematol. 2021. PMID: 33095415
72 results